Table 2 Ongoing phase 3 trials of anti-amyloid therapy
From: Clinical trials of new drugs for Alzheimer disease: a 2020–2023 update
Agent | Company | Synonyms | Therapeutic purpose | ClinicalTrials.gov identifier | Status |
|---|---|---|---|---|---|
Aducanumab (EMBARK) | Biogen, Neurimmune | BIIB037 | Immunotherapy (passive) | NCT04241068 | Active, not recruiting |
Aducanumab (ENVISION) | Immunotherapy (passive) | NCT05310071 | Recruiting | ||
Donanemab (TRAILBLAZER-ALZ 2) | Eli Lilly & Co | N3pG-Aβ Monoclonal Antibody | Immunotherapy (passive) | NCT04437511 | Active, not recruiting |
Donanemab (TRAILBLAZER-ALZ 3) | Immunotherapy (passive) | NCT05026866 | Recruiting | ||
Donanemab|/Aducanumab (TRAILBLAZER-ALZ 4) | Immunotherapy (passive) | NCT05108922 | Active, not recruiting | ||
Donanemab (TRAILBLAZER-ALZ 5) | Immunotherapy (passive) | NCT05508789 | Recruiting | ||
Donanemab (TRAILBLAZER-ALZ 6) | Immunotherapy (passive) | NCT05738486 | Recruiting | ||
Lecanemab (Clarity AD) | BioArctic AB, Biogen, Eisai | Lecanemab-irmb | Immunotherapy (passive) | NCT03887455 | Active, not recruiting |
Lecanemab (AHEAD 3–45 Study) | Immunotherapy (passive) | NCT04468659 | Recruiting | ||
Lecanemab and E2814 DIAN-TU-001 (E2814) | Eisai | Immunotherapy (passive) | NCT05269394 | Recruiting | |
Remternetug (TRAILRUNNER-ALZ1) | Eli Lilly & Co | LY3372993 | Immunotherapy (passive) | NCT05463731 | Recruiting |
Solanezumab (A4) | Eli Lilly & Co | LY2062430 | Immunotherapy (passive) | NCT02008357 | Active, not recruiting |
Solanezumab/ gantenerumab (DIAN-TU-001) | Immunotherapy (passive) | NCT01760005 | Recruiting | ||
ALZ-801 (APOLLOE4) | Alzheon | valiltramiprosate | Small molecule | NCT04770220 | Active, not recruiting |
Simufilam (RETHINK-ALZ) | Cassava Sciences | PTI-125 | Small molecule | NCT04994483 | Recruiting |
Simufilam (REFOCUS-ALZ) | Small molecule | NCT05026177 | Recruiting | ||
Simufilam | Small molecule | NCT05575076 | Enrolling through invitation |